| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1470-2045(19)30396-1 |
| P698 | PubMed publication ID | 31378459 |
| P50 | author | Paul Harnett | Q42873365 |
| Tarek M Meniawy | Q58414869 | ||
| P2093 | author name string | Michael Friedlander | |
| Bo Gao | |||
| Michael Millward | |||
| Song Mu | |||
| John Wu | |||
| Ben Markman | |||
| Linda Mileshkin | |||
| Virginia Paton | |||
| Christie Norris | |||
| Joanne Lundy | |||
| Alison Freimund | |||
| P2860 | cites work | Drug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United States | Q26767296 |
| Toxicities of Immunotherapy for the Practitioner | Q27008140 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 | ||
| Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group | Q33566395 | ||
| The DNA damage response, immunity and cancer | Q36567952 | ||
| Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer | Q37046405 | ||
| NKG2D ligands in tumor immunity | Q37287179 | ||
| Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis | Q37306007 | ||
| Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). | Q37832624 | ||
| The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer | Q38866964 | ||
| Mutational Landscape and Sensitivity to Immune Checkpoint Blockers | Q38889870 | ||
| Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial | Q46270437 | ||
| Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q50205173 | ||
| DNA Repair Deficiency and Immunotherapy Response. | Q54668423 | ||
| PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. | Q55004657 | ||
| The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions. | Q55417775 | ||
| Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy | Q57811628 | ||
| P433 | issue | 9 | |
| P921 | main subject | multicenter clinical trial | Q6934595 |
| P304 | page(s) | 1306-1315 | |
| P577 | publication date | 2019-08-01 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial | |
| P478 | volume | 20 |
| Q92395353 | Combining PARP inhibition with PD-1 inhibitors |
| Q96303222 | PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake |
| Q98945207 | Poly(ADP-ribose) polymerase inhibition: past, present and future |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q95841163 | Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors |
| Q90417275 | Tislelizumab: First Approval |
Search more.